Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Fabrication and Evaluation of a Dual-Targeting Nanoparticle Mediated Crispr/Cas9 Delivery to Combat Drug Resistance in Breast Cancer Cells Publisher



Tavazohi N1 ; Mirian M1 ; Varshosaz J2 ; Shiranibidabadi S2 ; Mohammad Sadeghi HM1 ; Khanahmad H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, 73461-81746, Iran
  2. 2. Department of Pharmaceutics and Novel Drug Delivery Systems Research Center, Faculty of Pharmacy Isfahan University of Medical Sciences, Isfahan, 73461-81746, Iran
  3. 3. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 73461-81746, Iran

Source: Journal of Drug Delivery Science and Technology Published:2023


Abstract

Breast cancer treatment is hampered by drug resistance which leads to recurrence and metastasis. Alteration of specific gene expression such as ERCC1 evidently acquires drug resistance in breast cancer patients. The genome-editing technique known as the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated Cas9 system (CRISPR-Cas9) has shown promise in targeting genes. The current study aimed to design and characterize an efficient cargo through a safe and noninvasive dual-targeted polyplex for CRISPR/Cas9 delivery to downregulate the ERCC1 gene expression, which is overexpressed in MCF-7 cisplatin-resistant cells. In this manner, a carrier based on chitosan (CS) polyplex was modified with hyaluronic acid conjugated triptorelin (HA-LHRH) as dual-targeting agents and loaded with CRISPR/Cas9 plasmids. CS/HA-LHRH/pCRISPR exhibited negligible toxicity and comparable transfection efficiency with Lipofectamine™ 3000. Dual-targeted polyplexes have boosted gene transfer by nearly two times that of single-targeted polyplexes (CS/HA/pCRISPR). Also, the dual-targeted polyplexes carrying plasmids of CRISPR/Cas9 enhanced drug sensitivity and decreased ERCC1 mRNA levels in MCF-7 cisplatin-resistant cell line, significantly. Our results suggest that CS/HA-LHRH/pCRISPR-mediated targeting of ERCC1 is practicable and could be potentially adopted as a novel therapeutic tool for removing platinum drug resistance in breast cancer cells. © 2023 Elsevier B.V.
Related Docs
View other Related Docs
1. Crispr Technology: A Versatile Tool to Model, Screen, and Reverse Drug Resistance in Cancer, European Journal of Cell Biology (2023)
2. Gene Network Analysis of Oxaliplatin-Resistant Colorectal Cancer to Target a Crucial Gene Using Chitosan/Hyaluronic Acid/Protamine Polyplexes Containing Crispr-Cas9, Biochimica et Biophysica Acta - General Subjects (2023)
3. Crispr–Cas9 in Genome Editing: Its Function and Medical Applications, Journal of Cellular Physiology (2019)
4. Harnessing Crispr/Cas9 Technology in Cardiovascular Disease, Trends in Cardiovascular Medicine (2020)
5. Crispr/Cas9, a New Approach to Successful Knockdown of Abcb1/P-Glycoprotein and Reversal of Chemosensitivity in Human Epithelial Ovarian Cancer Cell Line, Iranian Journal of Basic Medical Sciences (2018)
6. Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles, Frontiers in Pharmacology (2022)
7. Glutathione Targeted Tragacanthic Acid-Chitosan As a Non-Viral Vector for Brain Delivery of Mirna-219A-5P: An in Vitro/In Vivo Study, International Journal of Biological Macromolecules (2022)
8. Exploring Advanced Crispr Delivery Technologies for Therapeutic Genome Editing, Small Science (2024)
Experts (# of related papers)
View all Related Experts
Jaleh Varshosaz (6)
Mina Mirian (6)
Other Related Docs
9. Genetic Advancements in Breast Cancer Treatment: A Review, Discover Oncology (2025)
10. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
11. The Emerging Role of Circular Rnas in Cisplatin Resistance in Ovarian Cancer: From Molecular Mechanism to Future Potential, Non-coding RNA Research (2024)
12. Co-Delivery of Dasatinib and Mir-30A by Liposomes Targeting Neuropilin-1 Receptors for Triple-Negative Breast Cancer Therapy, Journal of Materials Chemistry B (2024)
13. Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin, Frontiers in Oncology (2021)
14. Gene Delivery by Pei-Nanocomplex Into Breast and Colorectal Tumor Cell Lines, the Impacts of N/P Ratio, Size and Type of the Cell; [Pei-Nanocomplex Tarafindan Meme Ve Kolorektal Tumor Hucre Hatlarinda Gen Dagitimi, N / P Oraninin, Hucrenin Boyutu Ve Turunun Etkileri], Fabad Journal of Pharmaceutical Sciences (2020)
15. Luteinizing Hormone-Releasing Hormone Targeted Poly(Methyl Vinyl Ether Maleic Acid) Nanoparticles for Doxorubicin Delivery to Mcf-7 Breast Cancer Cells, IET Nanobiotechnology (2016)
16. Potential Role of Thymoquinone to Treat Gastrointestinal Cancers: Insights Into Its Molecular Mechanisms, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
17. Targeted Delivery of Doxorubicin to Breast Cancer Cells by Magnetic Lhrh Chitosan Bioconjugated Nanoparticles, International Journal of Biological Macromolecules (2016)
18. Comparing the Transfection Efficiency of Cationic Monomer Ratios in Vinylimidazole and Aminoethyl Methacrylate Copolymers, International Journal of Pharmaceutics: X (2025)
19. Non-Viral Delivery Systems for Breast Cancer Gene Therapy, Current Gene Therapy (2017)
20. The Uniqueness of Albumin As a Carrier in Nanodrug Delivery, Molecular Pharmaceutics (2021)